HaemaLogiX has been in the spotlight as it advances a differentiated approach to multiple myeloma, the world’s second‑largest blood cancer. In a recent episode of BioBiz Buzz, CEO Dr Chris Baldwin outlined how the company is developing highly specific therapies targeting two novel antigens, KMA and LMA, found only on malignant plasma cells.

Its lead antibody, KappaMab, has already shown an 83% response rate in Phase IIb trials, while its partnered KMA.CAR‑T programme is progressing through early clinical development at the Peter MacCallum Cancer Centre.

With plans for an ASX IPO in 2026, HaemaLogiX is expanding its pipeline, scaling CAR‑T manufacturing, and positioning itself to address a major unmet need in a market exceeding $23 billion annually.

Listen to the full episode here: www.buzzsprout.com/2467194/episodes/18829609